Status:
COMPLETED
Safety and Efficacy of Enoxaparin and Hydroxychloroquine in COVID-19
Lead Sponsor:
Beni-Suef University
Conditions:
COVID-19 Pandemic
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
In this randomized controlled study, two hundred patients with positive PCR and laboratory confirmed COVID-19 will be classified randomly into four groups. The first group is the control group and wil...
Detailed Description
Although numerous therapeutic agents for COVID-19 are under investigation, an effective therapy remains a challenge among researchers. To date, hydroxychloroquine has been widely used for covid-19 tre...
Eligibility Criteria
Inclusion
- Laboratory confirmed COVID-19 infection by PCR test within 7 days prior to admission or during admission to hospital, CT or radiographic findings of pneumonia. Clinically suspected infection by symptoms like loss of smell and taste. No medical history that may interfere with treatment or with this clinical trial.
Exclusion
- Patient who had allergy or contraindication to HCQ, pregnant and lactating females, and patients with immune diseases, cardiac problem, had history of acute kidney injury or who received multiple cycles of anticoagulants were excluded from the study. Written informed consent was obtained from each participant. All study risks and benefits were thoroughly explained to patients' prior participation
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05311813
Start Date
June 1 2021
End Date
December 30 2021
Last Update
April 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beni-Suef University teaching Hospital
Banī Suwayf, Cairo Governorate, Egypt, 62511